CN101022812A - 固体和晶体伊班膦酸钠及其制备方法 - Google Patents

固体和晶体伊班膦酸钠及其制备方法 Download PDF

Info

Publication number
CN101022812A
CN101022812A CNA2005800285039A CN200580028503A CN101022812A CN 101022812 A CN101022812 A CN 101022812A CN A2005800285039 A CNA2005800285039 A CN A2005800285039A CN 200580028503 A CN200580028503 A CN 200580028503A CN 101022812 A CN101022812 A CN 101022812A
Authority
CN
China
Prior art keywords
sodium
ibandronate
diffraction pattern
peaks
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800285039A
Other languages
English (en)
Chinese (zh)
Inventor
R·利夫什茨-利伦
T·拜尔
J·阿伦希姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101022812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN101022812A publication Critical patent/CN101022812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Artificial Filaments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Liquid Crystal Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800285039A 2004-08-23 2005-08-23 固体和晶体伊班膦酸钠及其制备方法 Pending CN101022812A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US60/604,026 2004-08-23
US69086705P 2005-06-16 2005-06-16
US60/690,867 2005-06-16
PCT/US2005/030500 WO2006024024A2 (en) 2004-08-23 2005-08-23 Solid and crystalline ibandronate sodium and processes for preparation thereof

Publications (1)

Publication Number Publication Date
CN101022812A true CN101022812A (zh) 2007-08-22

Family

ID=35968334

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800285039A Pending CN101022812A (zh) 2004-08-23 2005-08-23 固体和晶体伊班膦酸钠及其制备方法

Country Status (12)

Country Link
US (1) US7563918B2 (https=)
EP (2) EP1930011B1 (https=)
JP (1) JP4559431B2 (https=)
KR (2) KR20090120011A (https=)
CN (1) CN101022812A (https=)
AT (2) ATE495747T1 (https=)
CA (1) CA2576659A1 (https=)
DE (2) DE602005025977D1 (https=)
ES (1) ES2358269T3 (https=)
IL (1) IL181298A (https=)
PT (2) PT1930011E (https=)
WO (1) WO2006024024A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
CN101111505B (zh) * 2005-02-01 2011-09-14 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物b
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3395338T (pt) 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
WO2008014510A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Limited Crystalline form a of ibandronic acid and process for the preparation
EP2009016A3 (en) 2006-11-16 2009-02-25 Teva Pharmaceutical Industries Ltd Process for preparing crystalline form of ibandronate sodium
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
BRPI0809548A8 (pt) 2007-04-11 2018-10-16 Hoffmann La Roche processo para a preparação do sal ácido- (mono-hidratado)-3- (n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfônico monossódico
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (en) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphic forms of Ibandronate sodium and processes for preparation thereof
EP2212338B1 (en) * 2007-10-26 2013-07-10 Chemo Ibérica, S.A. Polymorphic forms of ibandronate sodium and processes for preparation thereof
WO2009061336A1 (en) * 2007-11-05 2009-05-14 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (en) 2008-10-21 2010-04-28 Zentiva, k.s. Preparation of ibandronate trisodium
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
EP2429390B1 (en) 2009-05-15 2015-09-09 Nox Medical System and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
ES2525844T3 (es) 2010-06-25 2014-12-30 Nox Medical Ehf. Conector para correa biométrica
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
WO2015068041A1 (en) 2013-11-06 2015-05-14 Nox Medical Method, apparatus, and system for measuring respiratory effort
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2018033889A1 (en) 2016-08-19 2018-02-22 Nox Medical Method, apparatus, and system for measuring respiratory effort of a subject
US11896386B2 (en) 2017-06-02 2024-02-13 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
WO2019049097A1 (en) 2017-09-08 2019-03-14 Nox Medical Ehf SYSTEM AND METHOD FOR NON-INVASIVE DETERMINATION OF AN INTERNAL COMPONENT OF RESPIRATORY EFFORT

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
KR100763064B1 (ko) * 1999-05-21 2007-10-04 노파르티스 아게 제약 조성물 및 용도
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
ATE314862T1 (de) * 2000-05-05 2006-02-15 Hoffmann La Roche Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze
CA2410201C (en) * 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1228761A3 (en) * 2001-02-01 2003-01-15 Riderway Corporation Liquid pharmaceutical composition for treating bone diseases
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
TWI282283B (en) * 2002-05-17 2007-06-11 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
HRP20041013B1 (hr) * 2002-12-20 2013-10-25 F. Hoffmann - La Roche Ag Formulacija visoke doze ibandronata
CA2551230A1 (en) * 2003-12-23 2005-07-14 Lyogen Limited A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
EP2363401A1 (en) 2005-02-01 2011-09-07 F. Hoffmann-La Roche AG Ibandronate polymorph B
RU2368617C2 (ru) 2005-02-01 2009-09-27 Ф.Хоффманн-Ля Рош Аг Полиморфная модификация а ибандроната
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111505B (zh) * 2005-02-01 2011-09-14 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物b
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a
WO2008131160A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs

Also Published As

Publication number Publication date
KR20090120011A (ko) 2009-11-23
EP1930011A2 (en) 2008-06-11
IL181298A (en) 2011-04-28
DE602005025977D1 (de) 2011-03-03
CA2576659A1 (en) 2006-03-02
PT1930011E (pt) 2011-09-16
EP1713489A2 (en) 2006-10-25
IL181298A0 (en) 2007-07-04
DE202005021414U1 (de) 2008-03-20
EP1930011B1 (en) 2011-08-17
ATE495747T1 (de) 2011-02-15
WO2006024024A2 (en) 2006-03-02
JP4559431B2 (ja) 2010-10-06
ATE520406T1 (de) 2011-09-15
EP1930011A3 (en) 2008-06-18
PT1713489E (pt) 2011-03-03
JP2007512237A (ja) 2007-05-17
KR20070043043A (ko) 2007-04-24
US7563918B2 (en) 2009-07-21
WO2006024024A3 (en) 2006-06-29
US20070179119A1 (en) 2007-08-02
ES2358269T3 (es) 2011-05-09
EP1713489B1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
CN101022812A (zh) 固体和晶体伊班膦酸钠及其制备方法
EP2426104A1 (en) Tigecycline crystalline form and process for preparation thereof
CN101939303B (zh) 波生坦的晶型
KR20080032031A (ko) Ｏ-데스메틸벤라팍신의 결정형
WO2020014406A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
JP2009524685A (ja) ９−ヒドロキシ−リスペリドン（パリペリドン）の結晶型
JP2006249105A (ja) ゾルピデムヘミタートレイト
CN115515941A (zh) Mavacamten的固态形式及其制备工艺
KR20080055990A (ko) 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법
KR20080022595A (ko) 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
CN101472878A (zh) O-去甲基文拉法辛晶型
CN101421284A (zh) 伊班膦酸的结晶形式和其制备方法
CN1950331A (zh) 那格列奈的多晶型物
ES2368663T3 (es) Forma cristalina del ibandronato sódico.
CN115581118A (zh) 制造结晶形式的2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钠三水合物的方法
CN1674902A (zh) 新晶型的加替沙星
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법
MX2007002286A (en) Solid and crystalline ibandronate sodium and processes for preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070822